STOCK TITAN
  1. Home
  2. News
  3. REGN

Regeneron Pharmaceuticals Inc - REGN STOCK NEWS

Welcome to our dedicated page for Regeneron Pharmaceuticals news (Ticker: REGN), a resource for investors and traders seeking the latest updates and insights on Regeneron Pharmaceuticals stock.

Regeneron Pharmaceuticals Inc. (symbol: REGN) is a prominent American biotechnology company headquartered in Westchester County, New York, since its founding in 1988. The core mission of Regeneron is to discover, develop, and commercialize innovative products targeting a range of serious medical conditions. With a diverse portfolio, Regeneron focuses on therapies for eye diseases, cardiovascular conditions, cancer, and inflammatory disorders.

Among its marketed products, Eylea stands out as a treatment for wet age-related macular degeneration and other eye diseases. Praluent is designed to lower LDL cholesterol levels, while Dupixent addresses multiple immunological conditions. In the oncology sector, Libtayo is a key therapy, and Kevzara targets rheumatoid arthritis.

The company is also heavily invested in the development of monoclonal and bispecific antibodies, often in collaboration with Sanofi and other partners. These initiatives include cutting-edge technologies such as RNA interference (RNAi) with Alnylam and CRISPR-based gene editing with Intellia.

Regeneron's recent progress includes significant advancements in its clinical-stage pipeline, which comprises over 35 product candidates. The company's financial health remains robust, supported by strong revenue streams from collaboration with Sanofi and a strategic $3.0 billion share repurchase program authorized by the board.

Latest updates highlight the company's ongoing efforts in gene therapy, particularly in treating genetic deafness and solid tumors. Regeneron's commitment to pioneering genetic medicine and leveraging data insights from the Regeneron Genetics Center® positions it as a leader in the biopharmaceutical industry.

For more information, visit Regeneron Pharmaceuticals.

News

EYLEA® HD (aflibercept) Injection 8 mg Presentations at ARVO Reinforce Sustained and Clinically Meaningful Outcomes in Serious Retinal Diseases

Rhea-AI Summary

Regeneron Pharmaceuticals, Inc. announced positive long-term results from the EYLEA HD clinical program, showcasing durable efficacy and safety in patients with retinal diseases. The data presented at ARVO highlight the potential of EYLEA HD as a new standard of care for wet age-related macular degeneration, diabetic macular edema, and diabetic retinopathy. Notable presentations include results from the PHOTON and PULSAR trials, demonstrating maintained visual improvements with EYLEA HD.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.05%
Tags
none
-
News

Regeneron and Mammoth Biosciences Collaborate to Pursue Next-Generation CRISPR-Based Gene Editing for Multiple Diseases

Rhea-AI Summary
Regeneron Pharmaceuticals, Inc. (REGN) and Mammoth Biosciences, Inc. collaborate to advance in vivo CRISPR-based gene editing therapies for multiple diseases. Regeneron's AAV vectors and Mammoth's ultracompact gene editing systems aim to target tissues beyond the liver. Mammoth receives $100 million upfront payment and equity investment, with potential milestone payments totaling up to $370 million per target. Regeneron gains access to Mammoth's editing technologies for a period of five and a half years.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.75%
Tags
none
-
News

Regeneron to Showcase Progress in Advancing Novel Investigational Treatment Approaches for a Broad Range of Solid Tumors and Blood Cancers at ASCO

Rhea-AI Summary
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will showcase new data and updates on its oncology and hematology pipeline at the ASCO 2024 Annual Meeting. The presentations will cover investigational treatments for a variety of solid tumors and blood cancers, including REGN7075, a promising costimulatory bispecific antibody in combination with Libtayo. The company's commitment to cancer research and development of innovative therapies is evident in the diverse pipeline of checkpoint inhibitors and bispecific antibodies being presented at the conference.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.09%
Tags
none
News

Regeneron to Highlight Advances in Genetic Medicine Research at American Society of Gene and Cell Therapy (ASGCT)

Rhea-AI Summary
Regeneron Pharmaceuticals, Inc. to showcase genetic medicine research advancements at ASGCT conference, including results from clinical study of otoferlin gene therapy DB-OTO for genetic hearing loss. The company will present data on delivery systems, immune response modulation, and sustained treatment expression. Regeneron aims to overcome obstacles in genetic medicine implementation through innovative approaches. Promising early results from gene therapy programs raise hope for future treatments.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.8%
Tags
none
-
News

Linvoseltamab Pivotal Data Presented at AACR Reinforce High Response Rate that Deepens Over Time in Patients with Heavily Pre-Treated Multiple Myeloma

Rhea-AI Summary
Regeneron Pharmaceuticals, Inc. presents positive pivotal data on linvoseltamab for relapsed/refractory multiple myeloma at AACR Annual Meeting 2024. The data show promising results with high response rates, durable responses, and good safety profile.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.45%
Tags
none
-
News

Regeneron to Report First Quarter 2024 Financial and Operating Results and Host Conference Call and Webcast on May 2, 2024

Rhea-AI Summary
Regeneron Pharmaceuticals, Inc. (REGN) will report its Q1 2024 financial results on May 2, 2024. A conference call and webcast will be held at 8:30 AM Eastern Time. Participants can join via webcast or telephone.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.51%
Tags
conferences earnings
News

SillaJen Submits CSR to the US FDA for REN026 Study in Patients with RCC

Rhea-AI Summary
SillaJen submits CSR to the US FDA for REN026, a study on Pexa-Vec and cemiplimab in RCC patients. The study shows positive safety and efficacy results, with high response rates and overall survival. Collaboration with Regeneron Pharmaceuticals yields promising outcomes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.29%
Tags
none
-
News

Regeneron Provides Update on Biologics License Application for Odronextamab

Rhea-AI Summary
Regeneron Pharmaceuticals, Inc. receives Complete Response Letters from the FDA for odronextamab in relapsed/refractory follicular lymphoma and diffuse large B-cell lymphoma due to enrollment status issues in confirmatory trials. Despite this, no concerns were raised regarding clinical efficacy, safety, design, labeling, or manufacturing. Regeneron is actively enrolling patients in Phase 3 trials as part of the OLYMPIA program, aiming to revolutionize B-cell non-Hodgkin lymphoma treatment. The company is dedicated to collaborating with the FDA to expedite the availability of odronextamab for patients. Updates on enrollment and regulatory timelines are expected later this year, while EMA review continues for R/R DLBCL and R/R FL.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.64%
Tags
none
-
News

High School Seniors Win $1.8 Million at Regeneron Science Talent Search 2024 for Innovative Scientific Research on Artificial Intelligence, Cancer Metabolism and Mathematical Optimization

Rhea-AI Summary
Achyuta Rajaram, 17, from Exeter, NH, wins the top award of $250,000 in the Regeneron Science Talent Search 2024. The competition, in its 83rd year, highlights young innovators in STEM fields. Other winners include Thomas Cong and Michelle Wei.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.53%
Tags
none
News

Praluent® (alirocumab) Injection Receives FDA Approval to Treat Children with Genetic Form of High Cholesterol

Rhea-AI Summary
Regeneron Pharmaceuticals, Inc. (REGN) receives FDA approval to extend the use of Praluent for children aged 8 and older with heterozygous familial hypercholesterolemia (HeFH). The approval allows Praluent to be used as an adjunct to diet and other LDL-C lowering therapies, providing a new treatment option for children with high LDL-C levels.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.45%
Tags
fda approval

FAQ

What is the current stock price of Regeneron Pharmaceuticals (REGN)?

The current stock price of Regeneron Pharmaceuticals (REGN) is $680.03 as of January 22, 2025.

What is the market cap of Regeneron Pharmaceuticals (REGN)?

The market cap of Regeneron Pharmaceuticals (REGN) is approximately 76.3B.

What types of diseases does Regeneron Pharmaceuticals focus on?

Regeneron focuses on eye diseases, cardiovascular conditions, cancer, and inflammatory disorders.

What are some of Regeneron's key products?

Key products include Eylea for eye diseases, Praluent for lowering LDL cholesterol, Dupixent for immunology, Libtayo for oncology, and Kevzara for rheumatoid arthritis.

Who are some of Regeneron's notable collaborators?

Regeneron collaborates with Sanofi, Alnylam, and Intellia on various projects, including monoclonal and bispecific antibodies, RNAi, and CRISPR-based gene editing.

What recent financial steps has Regeneron taken?

Regeneron has initiated a $3.0 billion share repurchase program and reported strong financial performance in the first quarter of 2024.

How does Regeneron leverage genetic medicine?

Regeneron utilizes data-powered insights from the Regeneron Genetics Center® and employs proprietary technologies like VelociSuite® to advance drug development.

What is the significance of Eylea in Regeneron's product portfolio?

Eylea is a crucial product for treating wet age-related macular degeneration and other eye diseases, contributing significantly to Regeneron's revenue.

What advancements has Regeneron made in gene therapy?

Regeneron is progressing in gene therapy for genetic deafness and solid tumors, showcasing promising early results in clinical trials.

What is Dupixent used for?

Dupixent is used in treating various immunological conditions and has shown significant growth since its launch, treating over 850,000 patients.

What technologies does Regeneron use for drug development?

Regeneron uses proprietary technologies such as VelociSuite®, which includes platforms for producing optimized human antibodies and bispecific antibodies.

How does Regeneron contribute to scientific discovery?

Regeneron pushes the boundaries of scientific discovery with pioneering genetic medicine platforms and data insights, aiming to develop transformative therapies.
Stock REGN logo
Regeneron Pharmaceuticals Inc

Nasdaq:REGN

REGN Rankings

#176 Ranked by Market Cap
N/A Ranked by Dividends

REGN Stock Data

76.35B
106.22M
1.57%
90.64%
1.71%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
TARRYTOWN